Side-by-side comparison of AI visibility scores, market position, and capabilities
B2B clear aligner platform for dentists (CandidPro) with orthodontist-supervised remote monitoring; pivoted away from DTC in early 2024 to focus exclusively on dental professional partnerships.
Candid Co is a New York-based dental technology company that provides a clear aligner system marketed under the CandidPro brand for use by licensed dentists and orthodontists. Founded in 2017, the company originally launched as a direct-to-consumer aligner service but strategically pivoted in early 2024 to exit the DTC market entirely and concentrate on its professional provider network, where clinical outcomes are stronger and patient relationships are managed by dental professionals. CandidPro currently works with thousands of dental practices across the United States, providing aligner fabrication, orthodontist-driven treatment protocols, remote progress monitoring tools, and team training.
Global biopharma with $63.6B FY2024 revenue; $43B Seagen ADC acquisition rebuilds post-COVID pipeline; patent cliff 2026-2028 for Eliquis; activist Starboard Value pushing restructuring.
Pfizer is one of the world's largest biopharmaceutical companies, founded in 1849 by cousins Charles Pfizer and Charles Erhart in Brooklyn, New York, and now headquartered in New York City. The company trades on NYSE (PFE) and reported $63.6 billion in total revenues for FY2024, normalizing from pandemic highs of $100 billion-plus in 2021-2022 driven by Comirnaty COVID-19 vaccine revenues with BioNTech and Paxlovid COVID antiviral sales. CEO Albert Bourla has led a strategic pivot to reset the company's long-term growth profile, anchored by the landmark $43 billion acquisition of Seagen in December 2023, adding a world-class antibody-drug conjugate (ADC) oncology pipeline including Padcev, Tukysa, Adcetris, and Tivdak.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.